For the third quarter of 2026, analysts expect Anixa Biosciences to report zero revenue and a net loss of $0.08 per share, with the current $3.07 share price trading significantly below the $9.00 average price target.
The primary focus for investors remains clinical trial updates for the company's Phase 1 preventative breast cancer vaccine and CAR-T ovarian cancer therapy. As a pre-revenue biotechnology firm, Anixa's market valuation depends heavily on pipeline milestones rather than traditional earnings metrics.
Management is also expected to provide updates on its cash runway, which stood at $13.7 million at the end of the previous quarter, ensuring funding for operations through mid-2027.